Control group | Test group | p | |
---|---|---|---|
All probing sites | |||
PlI (%) | 29.0 (15.2–32.6) | 22.6 (14.8–34.1) | 0.589 |
GBI (%) | 7.6 (0.0–26.2) | 3.7 (1.9–10.2) | 0.529 |
PD (mm) | 1.1 (0.8–1.6) | 1.4 (1.1–1.5) | 0.358 |
REC (mm) | − 0.2 (− 0.6 – − 0.1) | − 0.3 (− 0.4 – − 0.1) | 0.672 |
CAL (mm) | 0.7 (0.5–1.2) | 1.0 (0.7–1.3) | 0.287 |
BOP (%) | 51.2 (36.0–64.4) | 49.4 (31.1–66.7) | 0.930 |
Sites with initial PD < 5 mm | |||
PlI (%) | 20.2 (15.1–30.9) | 16.1 (9.8–31.0) | 0.726 |
GBI (%) | 8.3 (0.0–22.5) | 3.3 (0.6–9.1) | 0.547 |
PD (mm) | 0.5 (0.3–0.7) | 0.7 (0.5–0.8) | 0.068 |
REC (mm) | − 0.2 (− 0.5 – − 0.1) | −0.2 (− 0.3–0.0) | 0.511 |
CAL (mm) | 0.3 (− 0.1–0.6) | 0.5 (0.2–0.7) | 0.140 |
BOP (%) | 46.9 (37.6–63.7) | 47.1 (29.7–65.3) | 0.884 |
Initially deep probing sites (PD ≥ 5 mm) without BOP | |||
PlI (%) | 4.5 (0.0–31.8) | 27.3 (0.0–35.4) | 0.753 |
GBI (%) | 0.0 (0.0–0.0) | 0.0 (− 3.3–0.0) | 0.601 |
PD (mm) | 2.0 (2.0–2.6) | 2.6 (2.2–2.9) | 0.110 |
REC (mm) | −0.6 (− 0.9–0.0) | −0.3 (− 0.5–0.0) | 0.274 |
CAL (mm) | 1.9 (1.0–2.3) | 2.3 (2.0–2.5) | 0.151 |
BOP (%) | / | / | / |
Initially diseased probing sites (PD ≥ 5 mm and BOP) | |||
PlI (%) | 31.0 (23.4–47.0) | 33.3 (22.2–46.9) | 0.804 |
GBI (%) | 7.9 (0.0–30.8) | 1.6 (0.0–14.8) | 0.486 |
PD (mm) | 2.6 (2.2–2.9) | 2.5 (2.3–3.1) | 0.849 |
REC (mm) | −0.4 (− 0.6–0.2) | −0.5 (− 0.6 – − 0.3) | 0.693 |
CAL (mm) | 2.1 (1.6–2.4) | 2.2 (1.5–2.7) | 0.942 |
BOP (%) | / | / | / |